Related Experiment Videos
Peritoneal dialysis-associated peritonitis caused by Dermabacter hominis
1Department of Microbiology, Regional Hospital, Trondheim, Norway. anrad@gmx.net
Journal of Clinical Microbiology
|August 30, 2001
Summary
Dermabacter hominis caused peritonitis in a peritoneal dialysis patient. Treatment with cefuroxime led to clinical cure, despite in vitro resistance, likely due to high drug concentrations achieved via intraperitoneal administration.
Area of Science:
- Microbiology
- Infectious Diseases
- Nephrology
Background:
- Peritonitis is a serious complication of peritoneal dialysis (PD).
- Identifying the causative pathogen is crucial for effective treatment.
- Dermabacter hominis is a rare cause of infection.
Observation:
- A patient undergoing peritoneal dialysis developed peritonitis.
- The causative agent was identified as Dermabacter hominis using phenotypic methods and 16S rRNA gene sequencing.
- The isolated D. hominis strain showed reduced susceptibility to cefuroxime in vitro (MIC = 12 mg/liter).
Findings:
- Despite in vitro reduced susceptibility, clinical cure was achieved with cefuroxime.
- High concentrations of cefuroxime were likely attained through intraperitoneal administration.
- This suggests successful treatment is possible even with borderline in vitro susceptibility.
Implications:
- Dermabacter hominis should be considered in the differential diagnosis of PD-associated peritonitis.
- Intraperitoneal antibiotic administration can overcome in vitro resistance in certain cases.
- Treatment strategies for PD-associated peritonitis may need to consider drug pharmacokinetics in the peritoneal cavity.